Posted by Michael Wonder on 24 Feb 2022
FDA approves treatment for wider range of patients with heart failure
24 February 2022 - Today, the U.S. FDA approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes.
